Back to top

Image: Bigstock

Is Vertex (VRTX) a Great Growth Stock?

Read MoreHide Full Article

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

One such company that might be well-positioned for future earnings growth is Vertex Pharmaceuticals Incorporated (VRTX - Free Report) . This firm, which is in the Medical - Biomedical and Genetics, saw EPS growth of 109.2% last year, and is looking great for this year too.

In fact, the current growth estimate for this year calls for earnings-per-share growth of 12.3%. Furthermore, the long-term growth rate is currently an impressive 22.5%, suggesting pretty good prospects for the long haul.

Vertex Pharmaceuticals Incorporated Price and Consensus

And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 8.5%. Thanks to this rise in earnings estimates, VRTX has a Zacks Rank#2 (Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider VRTX. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for VRTX as well.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.

See 7 breakthrough stocks now>>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Vertex Pharmaceuticals Incorporated (VRTX) - free report >>